Endo unit to sell anatomical pathology business
USA-based specialty health care company Endo Health Solutions (Nasdaq: ENDP) says that its wholly owned subsidiary, HealthTronics, has entered into a definitive agreement to sell its anatomical pathology business, HealthTronics Laboratory Solutions, to privately-held biotech firm Metamark Genetics, for an undisclosed amount.
As previously announced (The Pharma Letter June 7), Endo Health Solutions is pursuing strategic alternatives for HealthTronics, which was acquired in 2010 for $223 million, and believes the sale of HLS creates progress in this process.
Metamark is at the leading edge of research in cancer prognosis, which is a critical tool in determining appropriate cancer therapy. In the age of personalized medicine, particularly in oncology, Metamark's proprietary multiplex proteomic platform has the potential to reshape the landscape in cancer diagnosis and therapy.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze